Hannah Ellerbroek

Ms. Hannah Ellerbroek

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2022 in Addiction Science & Clinical Practice
Verified
Journal Article
Open access
PDF file
HEHannah Ellerbroek
Hannah Ellerbroek
SHSandra A. S. van Den Heuvel
Sandra A. S. van Den Heuvel
ADAlbert Dahan
Albert Dahan
HTHans Timmerman
Hans Timmerman
CKCornelis Kramers
Cornelis Kramers
ASArnt F. A. Schellekens
Arnt F. A. Schellekens
Background: Opioids are effective in pain-management, but long-term opioid users can develop prescription opioid use disorder (OUD). One treatment strategy in patients with OUD is rotating from a short-acting opioid to a long-acting opioid (buprenorphine/naloxone (BuNa) or methadone). Both BuNa and methadone have been shown to be effective strategies in patients with OUD reducing opioid misuse, however data on head-to-head comparison in patients with chronic non-malignant pain and prescription OUD are limited. Methods: This two-armed open-label, randomized controlled trial aims to compare effectiveness between BuNa and methadone in patients with chronic non-malignant with prescription OUD (n = 100). Participants receive inpatient rotation to either BuNa or methadone with a flexible dosing regimen. The primary outcome is opioid misuse 2 months after rotation. Secondary outcomes include treatment compliance, side effects, analgesia, opioid craving, quality of life, mood symptoms, cognitive and physical functioning over 2- and 6 months follow-up. Linear mixed model analysis will be used to evaluate change in outcome parameters over time between the treatment arms. Discussion: This is one of the first studies comparing buprenorphine/naloxone and methadone for treating prescription OUD in a broad patient group with chronic non-malignant pain. Results may guide future treatment for patients with chronic pain and prescription OUD. Trial registrationhttps://www.trialregister.nl/, NL9781

19 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HEHannah Ellerbroek
Hannah Ellerbroek
GKGerard Kalkman
Gerard Kalkman
CKCornelis Kramers
Cornelis Kramers
ASArnt F. A Schellekens
Arnt F. A Schellekens
BBBart Van den Bemt
Bart Van den Bemt
Background/Objectives: As long-term prescription opioid use is associated with increased morbidity and mortality, timely dose reduction of prescription opioids should be considered. However, most research has been conducted on patients using heroin. Given the differences between prescription and illicit opioid use, the aim of this review was to provide an overview of pharmacological strategies to reduce prescription opioid use or improve clinical outcomes for people who experience long-term prescription opioid use, including those with opioid use disorder. Methods: We conducted a systematic database search of PubMed, Embase, CINAHL, and the Cochrane Library. Outcomes included dose reduction, treatment dropout, pain, addiction, and outcomes relating to quality of life (depression, functioning, quality of life). Results: We identified thirteen studies (eight randomized controlled trials and five observational studies). Pharmacological strategies were categorized into two categories: (1) deprescribing (tapering) opioids or (2) opioid agonist treatment (OAT) with long-acting opioids. Tapering strategies decreased opioid dosage and had mixed effects on pain and addiction. OAT with buprenorphine or methadone led to improvements in pain relief and quality of life, with a slight (non-significant) preference for methadone in terms of treatment retention (RR = 1.10 [CI: 0.89–1.37]) but not for other outcomes. Most studies had high dropout rates and a serious risk of bias. Conclusions: Tapering reduced prescription opioid doses had mixed effects on pain. OAT improved clinical outcomes without dose reduction. Based on our review findings, there is no clear preference for either tapering or OAT. Tapering may be considered first as it reduces dependency, tolerance, and side effects, but is associated with adverse events and not always feasible. OAT can be a suitable alternative. Non-pharmacological interventions may facilitate tapering. Further research is needed to identify novel pharmacological strategies to facilitate opioid tapering. Registration: PROSPERO 2022 CRD42022323468.

24 May 2023 in Brain and Behavior
Verified
Journal Article
Open access
HEHannah Ellerbroek
Hannah Ellerbroek
IHImke Hanssen
Imke Hanssen
KLKaren Lathouwers
Karen Lathouwers
LCLinda Cillessen
Linda Cillessen
SDSander Dekkers
Sander Dekkers
ASArnt F. A. Schellekens
Arnt F. A. Schellekens
Background: Mindfulness‐based interventions have a positive impact on pain, craving, and well‐being in both patients with chronic pain and those with opioid use disorder (OUD). Although data are limited, mindfulness‐based cognitive therapy (MBCT) might be a promising treatment for patients with chronic noncancer pain combined with OUD. The aim of this qualitative study was to explore the feasibility and process of change during MBCT in this particular population.Methods: In this qualitative pilot study, 21 patients who were hospitalized for rotation to buprenorphine/naloxone as agonist treatment for chronic pain and OUD were offered MBCT. Semistructured interviews were conducted to explore experienced barriers and facilitators to MBCT. Patients who participated in MBCT were also interviewed on their perceived process of change.Results: Of 21 patients invited to participate in MBCT, 12 initially expressed interest but only four eventually participated in MBCT. The timing of the intervention, group format, somatic complaints, and practical difficulties were identified as the main barriers to participation. Facilitating factors included having a positive attribution toward MBCT, an intrinsic motivation to change, and practical support. The four MBCT participants mentioned several important mechanisms of change, including reduction of opioid craving and improved coping with pain.Conclusions: MBCT offered in the current study was not feasible for the majority of patients with pain and OUD. Changing the timing of MBCT by providing it at an earlier stage of the treatment and offering MBCT in an online format may facilitate participation.

20 March 2025 in BJPsych Open
Verified
Journal Article
Open access
PDF file
DVDamian A. Visser
Damian A. Visser
DEDaphne S. Everaerd
Daphne S. Everaerd
HEHannah Ellerbroek
Hannah Ellerbroek
JZJanneke R. Zinkstok
Janneke R. Zinkstok
ITIndira Tendolkar
Indira Tendolkar
ASArnt F. A Schellekens
Arnt F. A Schellekens
Background: The COVID-19 pandemic and lockdowns had a significant impact on mental well-being and (mental) healthcare systems globally. Aims: To describe trends and dynamics of out-patient prescribing of psychotropic medications during the COVID-19 pandemic in The Netherlands. Method: Dispensed psychotropic medication prescriptions during the COVID-19 pandemic from March 2020 to March 2022 were retrieved from national registry data. Numbers of total and incident dispensed prescriptions and defined daily doses (DDDs) were identified for six medication groups. Overall pandemic-related changes in prescribing trends were analysed using interrupted time-series analyses. Lockdown-related prescribing dynamics were described using monthly risk ratios. Results: No overall pandemic-related changes in prescribing were detected, except for alcohol addiction medication, for which a pre-pandemic decline in total dispensed prescriptions and DDDs levelled off during the pandemic: +10 prescriptions per week (95% CI 7–11, P ≤ 0.001) and +111 DDDs per week (95% CI 56–165, P = 0.001). Monthly prescribing dynamics showed transient increases in all medication groups during the second and third lockdown periods. There were decreases in dispensed incident antidepressant and opioid addiction medication prescriptions during the first lockdown (average risk ratios: 0.87 and 0.88 respectively), and DDDs of dispensed incident and total attention-deficit hyperactivity disorder medication prescriptions and incident benzodiazepine prescriptions were elevated from the end of the second lockdown (average risk ratios: 1.40, 1.12 and 1.17, respectively). Conclusions: These findings raise concerns regarding possible over- and under-prescribing during the pandemic. Further understanding of specific factors driving these changes is necessary to help prepare for future mental health(care) challenges.

3 August 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
HEHannah Ellerbroek
Hannah Ellerbroek
ASArnt F. A Schellekens
Arnt F. A Schellekens
GKGerard Kalkman
Gerard Kalkman
DVDamian A Visser
Damian A Visser
CKCornelis Kramers
Cornelis Kramers
EDEveline L A van Dorp
Eveline L A van Dorp
Objectives The COVID-19 pandemic and related lockdown measures disrupted global healthcare provision, including opioid prescribing. In North America, opioid sales declined while opioid-related deaths increased. In Europe, the effect of the pandemic on prescribing is not yet known. Given the ongoing increase in opioid-related harm and mortality, it is crucial to analyse the impact of the COVID-19 crisis and lockdown measures on opioid prescribing. Therefore, the objective of this study was to characterise opioid prescribing in the Netherlands during the COVID-19 pandemic. Design A nationwide register-based study characterising opioid prescribing using aggregated insurance reimbursement data. Setting Dutch healthcare during the first 2 years of the COVID lockdown. Participants The whole Dutch population. Primary and secondary outcome measures Comparing the number of opioid prescriptions during the pandemic with a prepandemic period using a risk ratio (RR), with separate analysis on the prescription type (first-time or repeat prescription), patients’ sex, age and socioeconomic status. We also explored lockdown effects. Results During the first lockdown, the total number of new opioid prescriptions and prescriptions to young patients (briefly) decreased (RR 0.88, 95% CI 0.88 to 0.89 and RR 0.73, 95% CI 0.70 to 0.75, respectively), but the overall number of opioid prescriptions remained stable throughout the pandemic compared with prepandemic. Women, older patients and patients living in lower socioeconomic areas received more opioids per capita, but the pandemic did not amplify these differences. Conclusions The pandemic appears to have had a limited impact on opioid prescribing in the Netherlands. Yet, chronic use of opioids remains an important public health issue.

19 December 2025 in PLOS ONE
Verified
Journal Article
Open access
CPCharlotte Ten Pas
Charlotte Ten Pas
VBViren Bahadoer
Viren Bahadoer
CKCornelis Kramers
Cornelis Kramers
ADAlbert Dahan
Albert Dahan
HEHannah Ellerbroek
Hannah Ellerbroek
NKNicole Kraaijvanger
Nicole Kraaijvanger
Objectives: Opioids are commonly prescribed in the Emergency Department (ED) for acute pain management. However, their use carries significant risks, including dependence and misuse. This study aims to gain insight into the perspectives of ED physicians and physician assistants (PAs) concerning the multifaceted role of the ED in problematic opioid use. This is crucial for reducing opioid-related harms. Design: A qualitative study, using semi-structured interviews. Setting and participants: Interviews were conducted with twenty-five ED physicians and PAs from four hospitals in the Netherlands. A diverse group participated in the study, representing different hospital settings and levels of working experience, Outcome measures and analysis: Reflexive thematic analysis was performed to develop key themes reflecting participants’ perspectives and attitudes towards the role of the ED in opioid related harms. Results: Two key themes were developed from the analysis. The first theme ‘Preventing opioid-related harms from an ED perspective’ underscores the careful approach emergency physicians take when prescribing opioids. This involves restricting opioid prescriptions to specific indications, considering alternative pain management options, limiting prescription durations, and involving patients in shared decision-making. Beyond their own prescribing practices, emergency care providers also collaborate with general practitioners, navigate patient expectations, and operate within a broader societal landscape where pain is increasingly viewed as intolerable. The second theme ‘Managing problematic opioid use at the ED’ highlights the difficulties faced by emergency care providers in treating individuals who are already using or dependent on opioids. This includes recognizing, intervening, referring, and managing cases of problematic opioid use. This theme also considers the involvement of other healthcare professionals, such as pain specialists and psychiatrists, as well as the roles and responsibilities of patients. Additionally, it considers the broader societal context, particularly the extent of opioid-related harms in the Netherlands, Conclusions: This study sheds light on the complexities surrounding opioid use and emergency care providers’ approach to mitigating opioid related harms while navigating patient needs and systemic challenges. EDs play a critical role in addressing opioid-related harms but face significant challenges. Strengthening provider education, integrating patient records, and enhancing partnerships with addiction services are key steps toward refining healthcare responses and policies for this ongoing public health crisis.